PRO-C6 (nordicPRO-C6™)
PopularA fragment of C-terminal type VIa3 collagen (Endotrophin), enabling non-invasive quantification of fibrogenesis, tissue remodeling and wound healing across chronic diseases.
Key features and values
- Measures a specific fragment of type VI collagen produced during collagen formation.
- Reflects active fibrogenesis and extracellular matrix remodeling in multiple organ systems.
- Enables non-invasive assessment of fibrotic progression in cardiovascular, renal, metabolic, and hepatic conditions.
- Supports monitoring of disease activity and response to anti-fibrotic therapies.
- Facilitates risk stratification and prognosis in patients with chronic and progressive diseases.
- Applicable for research into the mechanisms and dynamics of fibrosis and tissue repair.
- Complements other biomarkers to provide a comprehensive profile of collagen turnover and fibro-inflammatory activity.
Description
The PRO-C6 biomarker assay quantifies a neo-epitope fragment of type VI collagen generated during collagen formation, serving as a specific marker of active fibrogenesis and extracellular matrix remodeling. This non-invasive assay provides valuable insight into fibrotic processes underlying a wide range of chronic diseases, including those affecting the heart, liver, kidney, and metabolic systems. By capturing dynamic changes in type VI collagen synthesis, PRO-C6 supports disease monitoring, risk assessment, and therapeutic evaluation in clinical and research settings. Used alongside other collagen biomarkers, PRO-C6 enables a comprehensive assessment of collagen turnover and fibro-inflammatory progression, informing precision-medicine strategies in anti-fibrotic therapy and patient management.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
